FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

400 D C 20F40	
ton, D.C. 20549	OMB APPROVAL

wasiiiigtoii,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	OMB APPROVAL									
OMB Number: 3235-0287										
Estimated average burden										
l	hours per response:	0.5								

1. Name and Address of Reporting Person*  ANDREEFF DANE				<u>H</u>	2. Issuer Name and Ticker or Trading Symbol HELIUS MEDICAL TECHNOLOGIES, INC. [ HSDT ]							able)	Perso	on(s) to Issu 10% Ow Other (s)	ner	
(Last) (First) (Middle) C/O HELIUS MEDICAL TECHNOLOGIES INC. 642 NEWTOWN YARDLEY ROAD					3. Date of Earliest Transaction (Month/Day/Year) 08/08/2017						below)			below)`	,	
(Street) NEWTOWN PA 18940 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Inc						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date				2A. Deemed Execution Date if any (Month/Day/Yea		Code (Ins	nstr.		tr. 3, 4 and 5	5. Amoun Securities Beneficia Owned Fo Reported Transacti	s lly ollowing	Form:	Direct Indirect Etr. 4)	'. Nature of ndirect Beneficial Ownership Instr. 4)		
				Code V		Amount	ount (A) or Prid		(Instr. 3 and 4)							
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Transcription or Exercise (Month/Day/Year) if any Co		Transa Code (	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date of Secu (Month/Day/Year) Underly Derivat		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	n1(5)		
Stock Option (Right to Buy)	\$2.08 <sup>(1)</sup>	08/08/2017		A		100,000		(2)	08/08/2027	Class A Common Stock	100,000	\$0.00	100,000	0	D	

## Explanation of Responses:

- 1. Translated into US dollars from Canadian dollars based on buying rate from Federal Reserve Bank. USD \$1.0000 = CAD \$1.26675 on August 8, 2017; based on exercise price of CAD \$2.63.
- 2. Grant to the Reporting Person of a stock option under the Issuer's 2016 Stock Incentive Plan. The shares vest over four years, with 25% of the shares vesting on August 8, 2018 and the remaining shares vesting annually in three equal installments on August 8, 2019, 2020 and 2021, subject to the Reporting Person's continued service through each applicable vesting date.

## Remarks:

/s/ Dane Andreeff

08/11/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.